NCT03207230

Brief Summary

Study evaluates the relationships between daily physical activity levels (PAL) and functional capacity (VO2peak) in patients with dilated cardiomyopathy (DCM)

Trial Health

15
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Aug 2017

Shorter than P25 for not_applicable

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 27, 2017

Completed
5 days until next milestone

First Posted

Study publicly available on registry

July 2, 2017

Completed
1 month until next milestone

Study Start

First participant enrolled

August 1, 2017

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2018

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2018

Completed
Last Updated

August 13, 2019

Status Verified

August 1, 2019

Enrollment Period

7 months

First QC Date

June 27, 2017

Last Update Submit

August 9, 2019

Conditions

Outcome Measures

Primary Outcomes (1)

  • VO2max correlation with daily physical activity

    Maximal exercise capacity as measured by Max VO2 via CPET correlation with wearable device measures of daily physical activity

    2 weeks

Secondary Outcomes (2)

  • NYHA correlation with daily step count

    2 weeks

  • KCCQ correlation with daily step count

    2 weeks

Study Arms (1)

Standard

EXPERIMENTAL

All participants will perform the CPET at Baseline visit and will be provided with the Cardea SOLO, ActiGraph wGT3X-BT and Wavelet Wristband. The participants will be asked to response to KCCQ and Stanford 7 day recall surveys.

Device: Cardea SOLODevice: ActiGraph wGT3X-BTDevice: Wavelet Wristband

Interventions

Participants will be asked to wear everyday for 7 days after the Baseline visit. the monitor attaches to the skin with adhesive and records heart rate and heart rhythm.

Standard

Participants will be asked to wear everyday for 2 weeks after the Baseline visit. The wearable tracks activity and the step count during the day.

Standard

Participants will be asked to wear everyday for 2 weeks after the Baseline visit. The wearable measures the activity and the heart rate as measured by PPG sensor.

Standard

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Males and females, 18-75 years of age
  • Diagnosis of dilated cardiomyopathy
  • (Unexplained left ventricular enlargement (left ventricular end diastolic dimension (LVEDD) \>95th percentile for gender and height by echo or MRI)
  • (Left ventricular ejection fraction (LVEF) less than 50%)
  • CPET within 14 days prior to baseline visit with no intervening change in therapy
  • Echocardiogram or cardiac MRI within 1 year prior to baseline
  • Able to walk \>100ft without limitation
  • More than 30 minutes of exercise per week for at least 3 months prior to study enrollment, and plan to continue exercising for the next two weeks (duration of study).
  • Ability to provide informed consent and willingness to complete the study (including weekly phone follow-up)

You may not qualify if:

  • Heart failure hospitalization within four weeks prior to enrollment
  • Non-cardiac limitation of activity
  • \. Prior exercise-induced syncope or exercise-induced sudden death 5. Primary exercise mode is swimming or stationary biking 6. Participation in competitive or high intensity exercise against medical advice 7. Implantable Cardiverter Defibrillator (ICD) placement in the 2 months prior to enrollment 8. Plan for surgery, device implantation, or significant change in clinical management during the two weeks of the study

Contact the study team to confirm eligibility.

Sponsors & Collaborators

MeSH Terms

Conditions

Cardiomyopathy, Dilated

Condition Hierarchy (Ancestors)

CardiomegalyHeart DiseasesCardiovascular DiseasesCardiomyopathiesLaminopathiesGenetic Diseases, InbornCongenital, Hereditary, and Neonatal Diseases and Abnormalities

Study Officials

  • Matthew T Wheeler, MD PhD

    Stanford University

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NA
Masking
NONE
Purpose
OTHER
Intervention Model
SINGLE GROUP
Model Details: All participants enrolled in the study will receive the wearables and will be evaluated for the relationship between daily physical activity levels and functional capacity (VO2 peak).
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Clinical Assistant Professor

Study Record Dates

First Submitted

June 27, 2017

First Posted

July 2, 2017

Study Start

August 1, 2017

Primary Completion

March 1, 2018

Study Completion

March 1, 2018

Last Updated

August 13, 2019

Record last verified: 2019-08